Mycobacterium avium: Difference between revisions
No edit summary |
|||
| Line 5: | Line 5: | ||
*MAC primarily affects immunocompromised patients | *MAC primarily affects immunocompromised patients | ||
*Most commonly affects lungs | *Most commonly affects lungs | ||
**Productive cough, fever, dyspnea, fatigue, night sweats | **Productive [[cough]], [[fever]], [[dyspnea]], fatigue, night sweats | ||
*May present as: disseminated infection, lymphadenitis, abscess (cutaneous or brain) | *May present as: disseminated infection, lymphadenitis, [[abscess]] (cutaneous or brain) | ||
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ||
Latest revision as of 10:56, 15 February 2017
Background
- Mycobacterium Avium Complex (MAC) refers to species M. avium and M. intracellulare
Clinical Features
- MAC primarily affects immunocompromised patients
- Most commonly affects lungs
- May present as: disseminated infection, lymphadenitis, abscess (cutaneous or brain)
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
Table Overview
| ||||||||||||||||||||||||||||||||||||||||
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014